Literature DB >> 1271550

Stress incontinence: conservative therapy with sympathomimetic drugs.

B H Stewart, L H Banowsky, D K Montague.   

Abstract

There were 77 women with mild to moderate stress urinary incontinence treated with the sympathomimetic agent, phenylpropanolamine hydrochloride, combined with chlorpheniramine maleate and isopropamide iodide in a sustained release capsule (Ornade). The majority of these patients achieved significant improvement 3 months to 3 years after beginning therapy. A trial of conservative therapy is advisable for stress incontinence, especially when symptoms are mild or when the patients are in a poor risk category. Similar management of post-prostatectomy stress incontinence in men was disappointing. However, the occasional excellent results in patients with mild symptoms appear to justify a trial of conservative therapy before considering operative intervention in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1271550     DOI: 10.1016/s0022-5347(17)59280-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

Review 1.  Innovations in pharmacotherapy for stress urinary incontinence.

Authors:  Tracy W Cannon; Naoki Yoshimura; Michael B Chancellor
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-11-20

2.  Pharmacotherapy for stress urinary incontinence.

Authors:  Tracy W Cannon; Michael B Chancellor
Journal:  Rev Urol       Date:  2003

3.  Direct effect of amezinium on rabbit urethra: effect of estrogen and progesterone treatment.

Authors:  M Ishigooka; T Hashimoto; Y Suzuki; O Ichiyanagi; I Sasagawa; T Nakada
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1996

Review 4.  Current concepts in the treatment of disorders of micturition.

Authors:  K E Andersson
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 5.  Management of urinary incontinence in women.

Authors:  T C O'Dowd
Journal:  Br J Gen Pract       Date:  1993-10       Impact factor: 5.386

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.